Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HERON THERAPEUTICS, INC. /DE/HRTX · Entity 7133 | Director | January 30, 2026 | February 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HERON THERAPEUTICS, INC. /DE/
Report date January 30, 2026 · Filed February 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 53,960 |
Reported balance
After 2026-01-30 transaction · row 1
1 source rowRow 1 · 2026-01-30 · Grant · Acquired 53,960 · Balance 53,960 F1: The shares were granted as restricted stock units which vest in full on January 30, 2027. Each restricted stock unit represents a contigent right to receive one share of common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were granted as restricted stock units which vest in full on January 30, 2027. Each restricted stock unit represents a contigent right to receive one share of common stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 30, 2026 Filed Feb 3, 2026 15:00 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantCommon Stock | 53,960 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-034626 · ownership.xml · nonDerivative · entry 1 Dissanaike Sharmila · CIK 0001885069 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,960 F1 · shares: The shares were granted as restricted stock units which vest in full on January 30, 2027. Each restricted stock unit represents a contigent right to receive one share of common stock. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 22:34 UTC Amendment | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantStock Option (Right to Buy) · Derivative | 35,900 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0000950170-25-013770 · ownership.xml · derivative · entry 2 Dissanaike Sharmila · CIK 0001885069 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,900 Underlying: Common Stock · 35,900 shares Expires 2035-01-31 F2 · derivative.exercise_date: The stock options vest and become exercisable in 12 equal monthly installments beginning one month after the date of grant. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 22:34 UTC Amendment | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantCommon Stock | 17,950 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-013770 · ownership.xml · nonDerivative · entry 1 Dissanaike Sharmila · CIK 0001885069 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,180 F1 · shares: The shares were granted as restricted stock units which vest in full on January 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| January 30, 2025 Filed Feb 3, 2025 16:48 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantStock Option (Right to Buy) · Derivative | 35,900 | $1.73 Strike: $1.73 | $62,107.00 |
DisclosureSEC source: 0000950170-25-012107 · ownership.xml · derivative · entry 2 Dissanaike Sharmila · CIK 0001885069 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,900 Underlying: Common Stock · 35,900 shares Expires 2035-01-30 F2 · derivative.exercise_date: The stock options vest and become exercisable in 12 equal monthly installments beginning one month after the date of grant. Read SEC document |
| January 30, 2025 Filed Feb 3, 2025 16:48 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantCommon Stock | 17,950 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-012107 · ownership.xml · nonDerivative · entry 1 Dissanaike Sharmila · CIK 0001885069 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,180 F1 · shares: The shares were granted as restricted stock units which vest in full on January 30, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| January 19, 2024 Filed Jan 20, 2024 02:02 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantStock Option (Right to Buy) · Derivative | 83,685 | $0.00 Strike: $2.09 | $0.00 |
DisclosureSEC source: 0001209191-24-001978 · doc4.xml · derivative · entry 2 Dissanaike Sharmila · CIK 0001885069 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,685 Underlying: Common Stock · 83,685 shares Expires 2034-01-19 F2 · derivative.exercise_date: The stock options vest and become exercisable in 12 equal monthly installments beginning one month after the date of grant. Read SEC document |
| January 19, 2024 Filed Jan 20, 2024 02:02 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantCommon Stock | 13,948 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-001978 · doc4.xml · nonDerivative · entry 1 Dissanaike Sharmila · CIK 0001885069 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,230 F1 · shares: The shares were granted as restricted stock units which vest in full on January 19, 2025. Read SEC document |
| December 16, 2022 Filed Dec 20, 2022 22:20 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantStock Option (Right to Buy) · Derivative | 77,160 | $0.00 Strike: $2.74 | $0.00 |
DisclosureSEC source: 0001209191-22-062187 · doc4.xml · derivative · entry 2 Dissanaike Sharmila · CIK 0001885069 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,160 Underlying: Common Stock · 77,160 shares Expires 2032-12-16 F2 · derivative.exercise_date: The stock options vest and become exercisable in 12 equal monthly installments beginning one month after the date of grant. Read SEC document |
| December 16, 2022 Filed Dec 20, 2022 22:20 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantCommon Stock | 38,580 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-062187 · doc4.xml · nonDerivative · entry 1 Dissanaike Sharmila · CIK 0001885069 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,282 F1 · shares: The shares were granted as restricted stock units which vest in full on December 16, 2023. Read SEC document |
| December 22, 2021 Filed Dec 23, 2021 23:56 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantStock Option (Right to Buy) · Derivative | 20,903 | $0.00 Strike: $9.81 | $0.00 |
DisclosureSEC source: 0001209191-21-071168 · doc4.xml · derivative · entry 2 Dissanaike Sharmila · CIK 0001885069 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,903 Underlying: Common Stock · 20,903 shares Expires 2031-12-22 F2 · derivative.exercise_date: The stock options vest and become exercisable in 12 equal monthly installments beginning one month after the date of grant. Read SEC document |
| December 22, 2021 Filed Dec 23, 2021 23:56 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantCommon Stock | 10,452 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-071168 · doc4.xml · nonDerivative · entry 1 Dissanaike Sharmila · CIK 0001885069 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,702 F1 · shares: The shares were granted as restricted stock units which vest in full on December 22, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.